Cochrane for Clinicians
Putting Evidence into Practice
Topiramate for the Prophylaxis of Episodic Migraine in Adults
FREE PREVIEW. AAFP members and paid subscribers: Log in to get free access. All others: Purchase online access.
FREE PREVIEW. Purchase online access to read the full version of this article.
Am Fam Physician. 2014 Jul 1;90(1):24.
Author disclosure: No relevant financial affiliations.
Is topiramate (Topamax) an effective prophylactic medication for adults with episodic migraine?
Topiramate in a dosage of 100 mg per day is effective for decreasing the frequency of headaches in adults with episodic migraine. (Strength of Recommendation: A, based on consistent, good-quality patient-oriented evidence.)
Migraine headaches are common, affecting approximately 18% of women and 6% of men in the United States.1 Episodic migraine describes a headache frequency of fewer than 15 days per month as opposed to chronic migraine, in which headaches occur 15 or more days per month. Pharmacologic migraine treatment options include acute and preventive therapies. Population-based studies suggest that approximately 26% of persons who have migraines need preventive therapy, but only 13% use it.1
Topiramate is an antiepileptic drug used as preventive therapy for migraines.2 This meta-analysis studied whether topiramate was effective in reducing the occurrence of migraines and/or improving migraine-related quality of life in patients with episodic migraine. Seventeen prospective, controlled trials of topiramate were included in this analysis. Nine of these studies compared topiramate with placebo and found that it reduced headache frequency by 1.2 attacks per 28 days (mean difference = −1.20; 95% confidence interval [CI], −1.59 to −0.80). Patients taking topiramate daily were more likely to report a 50% or more reduction in headache frequency compared with patients taking placebo (relative risk = 2.02; 95% CI, 1.57 to 2.60). The number needed to treat for a 50% reduction in migraine headaches with topiramate vs. placebo was 4 (95% CI, 3 to 6).
Topiramate in dosages of 50 to 200 mg daily improves outcomes compared with placebo. A meta-analysis of three studies showed that the 100-mg dose was more effective at reducing headache frequency than the 50-mg dose (mean difference = −0.71; 95% CI, −1.32 to −0.10), and equivalent to the 200-mg dose. In trials that compared topiramate with placebo, seven adverse effects were reported by at least three studies: anorexia, fatigue, memory problems, nausea, paresthesia, taste disturbance, and weight loss. All adverse effects except nausea were significantly more common in persons taking 100 mg of topiramate daily vs. placebo. Topiramate is known to cause birth defects if taken during pregnancy, and should be used with caution in women of childbearing age.
Guidelines from the American Academy of Neurology, the American Headache Society, and the Canadian Headache Society list topiramate as a first-line agent to prevent episodic migraine. Other first-line agents are beta blockers (metoprolol, propranolol, and timolol); the antiepileptic valproate (Depacon); and butterbur, an herbal medication.3 The American Academy of Neurology suggests offering preventive treatment when an individual reports one of the following: six or more headache days per month, four or more headache days with at least some impairment, or three or more headache days with severe impairment or requiring bed rest. Only a few head-to-head drug comparison trials are available, and these suggest that topiramate is probably as effective for the prevention of migraines as other recommended first-line agents (e.g., propranolol, valproate).2 In conclusion, topiramate in a dosage of 100 mg daily is a reasonable choice for migraine prophylaxis in patients with episodic migraine.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD010610.
Linde M, Mulleners WM, Chronicle EP, McCrory DC. Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;(6):CD010610.
1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–349.
2. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society [published correction appears in Neurology. 2013;80(9):871]. Neurology. 2012;78(17):1337–1345.
3. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012;52(6):930–945.
These are summaries of reviews from the Cochrane Library.
The series coordinator for AFP is Corey D. Fogleman, MD, Lancaster General Hospital Family Medicine Residency, Lancaster, Pa.
A collection of Cochrane for Clinicians published in AFP is available at http://www.aafp.org/afp/cochrane.
Copyright © 2014 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Dec 1, 2016
Access the latest issue of American Family Physician